An accomplished leader, Barry has over 25 years of international medical device experience spanning roles in R&D, Sales & Marketing & C Suite. Barry graduated from University of Limerick in 1996 with an Honours Bachelor of Technology Degree. Postgraduate he competed an Executive MBA at Dublin City University, a Higher Diploma in International Selling, Dublin Institute of Technology and an Executive Leadership Program at Cambridge University, Judge Business School. A postgraduate R&D role with Boston Scientific Galway set the foundation for Barry’s Med Tech career. Thereafter, commercial customer facing roles of increasing responsibility with Johnson & Johnson. As Franchisee Director he led the Ethicon surgical division of J&J’s business in the Irish market. After almost a decade at J&J Barry departed to pursue a personal vision, as founding CEO he established neoSurgical Ltd. Barry led neoSurgical from its Irish inception to international commercialisation scale up and ultimately exit. Demonstrably built and led the development of early device concepts (a suite of class III surgical wound products) through CE and FDA regulatory approval. Barry is a named inventor on several granted patents and proud of his contribution to this area of surgery. Barry brings a proven ability to analyse market and competitor trends, identify global business opportunities, build new sales channels, and penetrate markets. An industry-savvy executive who can drive new product development from initial market assessment through launch and accelerate growth for both new and existing products. Barry is passionate about medical technology, innovation and thrives in anticipating and planning for the needs of people and organisations.

Lior Teitelbaum is Principal, Venture Investments at Johnson & Johnson Innovation – JJDC, Inc., where he is responsible for investments in the MedTech, Pharmaceutical, and Biotechnology spaces across Israel/Europe. He brings over 18 years of experience in founding, financing and operating in early-stage life sciences companies. Lior Holds an MBA from Tel Aviv U and an MSC from the Weizmann Institute.

Anton brings extensive experience in company development, product creation, commercialization and customer relationship management. Uniquely suited to Loci Orthopaedics mission, Anton’s experience of bringing a novel orthopedics product from concept, through US regulatory approval, and into a pivotal US-based clinical trial, will be directly applicable to our future here at Loci. His in-depth technical knowledge will complete an outstanding combination of clinical and commercial acumen that is directly applicable to Loci Orthopaedics. Anton is co-founder and CEO of MoxiMed, an orthopaedics medical device company. He has been a key member of the MoxiMed team that has brought a product from concept to clinical use.

Daniel O’Mahony is a Partner at Seroba Life Sciences venture capital fund and brings a wealth of experience from pharma and medtech industry in product development, clinical trials, product commercialisation, strategic planning, licensing, corporate venturing, technology commercialisation and venture capital investment. He held senior appointments at Elan Corporation plc from 1994-2003, where he was involved in technology and product development and in corporate venturing. He established the Technology Transfer Office at NUI Galway in 2005. Daniel graduated with a Ph.D. from University College Cork, holds a business degree in technology management from the Smurfit Business School, University College Dublin and has held academic appointments in Ireland and USA. He currently sits on a number of boards including Perfuze, Loci Orthopaedics, Carballo Group Limited and ATXA Therapeutics. He previously sat on the boards of PQ Bypass (acquired by Endologix), Novate Medical (acquired by BTG), Apica Cardiovascular (acquired by Thoratec), Covagen (acquired by Cilag/Janssen Pharmaceutical Companies of the Johnson & Johnson Group), Atlantic Therapeutics (acquired by Caldera Medical inc), Stokes Bio (acquired by Life Technologies), Straatum (acquired by Lam Research Corporation). Seroba is currently investing from its new fund, Fund IV with a focus in pharma /biotech and medtech investments. He has published in several scientific journals and is co-inventor on numerous patent families.